Literature DB >> 9660466

Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice.

G W Anderson1, D G Heath, C R Bolt, S L Welkos, A M Friedlander.   

Abstract

A single, subcutaneous, 30-microg dose of either a combination of the Yersinia pestis proteins F1+V or a F1-V fusion protein adsorbed to the adjuvant aluminum hydroxide, protected Hsd:ND4 mice for one year against pneumonic plague. The recombinant F1+V vaccine provided significant protection as early as day 14 postimmunization. The current Plague Vaccine USP in a single 0.2-ml dose did not provide significant protection in this mouse model. Antibody titers to F1 and V peaked at approximately 5-12 weeks postimmunization and were still detectable one year later. These F1 and V subunit vaccines may offer effective long-term immunity with a reduced dosage schedule when compared with the presently licensed, formalin-killed, whole-cell vaccine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9660466     DOI: 10.4269/ajtmh.1998.58.793

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  39 in total

1.  Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague.

Authors:  Jeremy L Goodin; David F Nellis; Bradford S Powell; Vinay V Vyas; Jeffrey T Enama; Lena C Wang; Patrick K Clark; Steven L Giardina; Jeffery J Adamovicz; Dennis F Michiel
Journal:  Protein Expr Purif       Date:  2006-12-31       Impact factor: 1.650

2.  Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.

Authors:  Danielle A Wagner; Sean M Kelly; Andrew C Petersen; Nathan Peroutka-Bigus; Ross J Darling; Bryan H Bellaire; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Acta Biomater       Date:  2019-10-11       Impact factor: 8.947

3.  An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model.

Authors:  E D Williamson; P M Vesey; K J Gillhespy; S M Eley; M Green; R W Titball
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

4.  LcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague.

Authors:  Wei Sun; Shilpa Sanapala; Jeremy C Henderson; Shandiin Sam; Joseph Olinzock; M Stephen Trent; Roy Curtiss
Journal:  Infect Immun       Date:  2014-08-11       Impact factor: 3.441

5.  Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new-generation recombinant plague vaccine.

Authors:  Tatiana E Erova; Jason A Rosenzweig; Jian Sha; Giovanni Suarez; Johanna C Sierra; Michelle L Kirtley; Christina J van Lier; Maxim V Telepnev; Vladimir L Motin; Ashok K Chopra
Journal:  Clin Vaccine Immunol       Date:  2012-12-12

Review 6.  Intraspecific diversity of Yersinia pestis.

Authors:  Andrey P Anisimov; Luther E Lindler; Gerald B Pier
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

7.  Human anti-plague monoclonal antibodies protect mice from Yersinia pestis in a bubonic plague model.

Authors:  Xiaodong Xiao; Zhongyu Zhu; Jennifer L Dankmeyer; Michael M Wormald; Randy L Fast; Patricia L Worsham; Christopher K Cote; Kei Amemiya; Dimiter S Dimitrov
Journal:  PLoS One       Date:  2010-10-13       Impact factor: 3.240

8.  Long-term observation of subunit vaccine F1-rV270 against Yersinia pestis in mice.

Authors:  Zuyun Wang; Lei Zhou; Zhizhen Qi; Qingwen Zhang; Ruixia Dai; Yonghai Yang; Baizhong Cui; Hu Wang; Ruifu Yang; Xiaoyi Wang
Journal:  Clin Vaccine Immunol       Date:  2009-11-25

9.  The V antigen of Pseudomonas aeruginosa is required for assembly of the functional PopB/PopD translocation pore in host cell membranes.

Authors:  Julien Goure; Alexandrine Pastor; Eric Faudry; Jacqueline Chabert; Andréa Dessen; Ina Attree
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

10.  Characterization of a Cynomolgus Macaque Model of Pneumonic Plague for Evaluation of Vaccine Efficacy.

Authors:  Patricia Fellows; Jessica Price; Shannon Martin; Karen Metcalfe; Robert Krile; Roy Barnewall; Mary Kate Hart; Hank Lockman
Journal:  Clin Vaccine Immunol       Date:  2015-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.